Scholarlink

<p>Tumor-associated macrophages (TAMs) in glioblastoma (GBM) often adopt tumor-supportive phenotypes, but the underlying signaling in TAMs is unclear. Interleukin-10 (IL-10) is frequently upregulated in tumors, but the understanding of IL-10 in the tumor immune microenvironment is controversial. This study aims to determine the roles of IL-10 receptor alpha (IL-10Rα) signaling in TAMs and explore the targetable mediators for GBM treatment. We found that growth of intracranial GBMs was delayed in engineered mice with myeloid-specific knock-out of IL-10Rα, which was accompanied by changes in TAM phenotypes. Meanwhile, IL-10 expression in GBMs, which was largely accredited to TAMs, were not affected by IL-10Rα deficiency. RNA-sequencing analysis and immunostaining revealed cyclooxygenases COX-1/2 as potential downstream effectors of IL-10Rα in TAMs. Pharmacological inhibition of COX-1/2 suppressed bone-marrow derived macrophages (BMDM) polarization upon IL-4/IL-10 treatment. Consistently, the COX inhibitor NS-398 mitigated intracranial GBM growth. In summary, we not only demonstrated the crucial roles of IL-10Rα but also discovered COX-1/2 as downstream targets for pro-tumor phenotypes of TAMs in GBMs. These findings provide new clues for future development of immunotherapies for GBM treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cyclooxygenase-mediated IL-10Rα signaling underlies pro-tumor phenotypes of macrophages in glioma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Jiahui Zhou,
  • Bingxi Shi,
  • Qiangsheng Li,
  • Fangzhen Li,
  • Zhiwen Zhang,
  • Qiuhong Zhu,
  • Huipeng Wang,
  • Wei Wang,
  • Hai-bo Wu,
  • Aili Zhang,
  • Bofeng Li,
  • Wenchao Zhou

摘要

Tumor-associated macrophages (TAMs) in glioblastoma (GBM) often adopt tumor-supportive phenotypes, but the underlying signaling in TAMs is unclear. Interleukin-10 (IL-10) is frequently upregulated in tumors, but the understanding of IL-10 in the tumor immune microenvironment is controversial. This study aims to determine the roles of IL-10 receptor alpha (IL-10Rα) signaling in TAMs and explore the targetable mediators for GBM treatment. We found that growth of intracranial GBMs was delayed in engineered mice with myeloid-specific knock-out of IL-10Rα, which was accompanied by changes in TAM phenotypes. Meanwhile, IL-10 expression in GBMs, which was largely accredited to TAMs, were not affected by IL-10Rα deficiency. RNA-sequencing analysis and immunostaining revealed cyclooxygenases COX-1/2 as potential downstream effectors of IL-10Rα in TAMs. Pharmacological inhibition of COX-1/2 suppressed bone-marrow derived macrophages (BMDM) polarization upon IL-4/IL-10 treatment. Consistently, the COX inhibitor NS-398 mitigated intracranial GBM growth. In summary, we not only demonstrated the crucial roles of IL-10Rα but also discovered COX-1/2 as downstream targets for pro-tumor phenotypes of TAMs in GBMs. These findings provide new clues for future development of immunotherapies for GBM treatment.